Debt-to-EBITDA measures a company's ability to pay off its debt.
Orgenesis's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2021 was $6.38 Mil. Orgenesis's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2021 was $5.46 Mil. Orgenesis's annualized EBITDA for the quarter that ended in Dec. 2021 was $-17.32 Mil.
Orgenesis's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2021 was -0.68.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Orgenesis's Debt-to-EBITDA or its related term are showing as below:
ORGS'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -3.84 Med: -0.74 Max: -0.05
Current: -0.78
During the past 13 years, the highest Debt-to-EBITDA Ratio of Orgenesis was -0.05. The lowest was -3.84. And the median was -0.74.
Orgenesis Debt-to-EBITDA Historical Data
The historical data trend for Orgenesis's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
|
Orgenesis Annual Data
|
|
Trend |
Nov12 |
Nov13 |
Nov14 |
Nov15 |
Nov16 |
Nov17 |
Nov18 |
Dec19 |
Dec20 |
Dec21 |
| Debt-to-EBITDA |
|
|
|
|
|
|
-0.78 |
-0.30 |
-0.74 |
-0.14 |
-0.78 |
|
Orgenesis Quarterly Data
|
|
Feb17 |
May17 |
Aug17 |
Nov17 |
Feb18 |
May18 |
Aug18 |
Nov18 |
Mar19 |
Jun19 |
Sep19 |
Dec19 |
Mar20 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
| Debt-to-EBITDA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
-0.06 |
5.96 |
-1.60 |
-0.34 |
-0.68 |
Competitive Comparison
For the Biotechnology subindustry, Orgenesis's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Orgenesis Debt-to-EBITDA Distribution
For the Biotechnology industry and Healthcare sector, Orgenesis's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Orgenesis's Debt-to-EBITDA falls into.
Orgenesis Debt-to-EBITDA Calculation
Debt-to-EBITDA measures a company's ability to pay off its debt.
Orgenesis's Debt-to-EBITDA for the fiscal year that ended in Dec. 2021 is calculated as
Orgenesis's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2021 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Dec. 2021) EBITDA data.
Orgenesis Business Description
Traded in Other Exchanges
Address
20271 Goldenrod Lane, Germantown, MD, USA, 20876
Orgenesis Inc is a part of the healthcare sector. It is a fully-integrated biopharmaceutical company focused on developing trans-differentiation technologies for diabetes and vertically integrating manufacturing that can optimize its abilities to scale-up its technologies for clinical trials and eventual commercialization. The group operates in two segments namely CDMO and POC. The company is also engaged in applying its disciplined execution to emerging technologies of other cell therapy markets in such areas as cell-based cancer immunotherapies and neurodegenerative diseases.
Executives
| Sidransky David |
director |
JOHNS HOPKINS UNIVERSITY 720 RUTLAND AVENUE BALTIMORE MD 21205 |
| Reithinger Neil |
officer: CFO, Treasurer and Secretary |
14950 N. 83RD PLACE SUITE 1 SCOTTSDALE AZ 85260 |
| Philips Mario |
director |
C/O ATMI, INC DANBURY CT 06810 |
| Ferber Sarah |
officer: Chief Scientific Officer |
17B HAHASKALA STREET TEL AVIV L3 67890 |
| Yachin Guy |
director |
7 ORCHARD WAY N POTOMAC MD 20854 |
| Nanda Ashish |
director |
2301, 23RD FLOOR, TIFFANY TOWERS CLUSTER W, JLT, DUBAI, UAE DUBAI C0 4452 |
| Bedoret Denis |
officer: See Remarks |
48, RUE AUGUSTE PICCARD GOSSELIES C9 6041 |
| Universite Libre De Bruxelles |
other: less than 10% |
AVENUE F, ROOSEVELT, 50 BRUSSELS C9 1050 |
| Theodorus Ii Sa |
other: less than 10% |
ALLEE DE LA RECHERCHE, 12 BRUSSELS C9 1070 |
| Theodorus Sca |
other: less than 10% |
ALLEE DE LA RECHERCHE, 12 BRUSSELS C9 1070 |
| Belenger Olivier |
other: less than 10% |
DIEWEG, 69 BRUSSELS C9 1070 |
| Shvartz Oded |
10 percent owner |
130 BIRUINTEI BVD. PANTELIMON, ILFOV S5 0000000 |
| Bultot Hugues |
director |
AVENUE DE L??HORIZON 24 WOLUWE SAINT PIERRE C9 1150 |
| Buyse Chris Georges Frans |
director |
BAILLET LATOURLEI 119A BRUSSELS C9 2390 |
| Tenne Joseph |
officer: CFO Treasurer Secretary |
6225 NEIL ROAD, SUITE 300 C/O ORMAT TECHNOLOGIES, INC. RENO NV 89511 |
Orgenesis Headlines
By Seekingalpha 2021-01-28
By Seekingalpha 2021-05-17
By Seekingalpha 2021-11-06
My Portfolios
Create New Portfolio
Portfolio Contest
My Gurus
Personalize
Premium Gurus 
0.03(1.43%) Volume: 54,822 4:00PM EDT
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
NAS:ORGS has been successfully added to your 